KR20170137113A - C형 간염 바이러스 중합효소의 저해제 - Google Patents

C형 간염 바이러스 중합효소의 저해제 Download PDF

Info

Publication number
KR20170137113A
KR20170137113A KR1020177030184A KR20177030184A KR20170137113A KR 20170137113 A KR20170137113 A KR 20170137113A KR 1020177030184 A KR1020177030184 A KR 1020177030184A KR 20177030184 A KR20177030184 A KR 20177030184A KR 20170137113 A KR20170137113 A KR 20170137113A
Authority
KR
South Korea
Prior art keywords
ethoxy
hcv
inhibitor
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020177030184A
Other languages
English (en)
Korean (ko)
Inventor
이리나 씨. 제이콥슨
마이클 디. 피세
샘 에스. 이
Original Assignee
코크리스탈 파마, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코크리스탈 파마, 아이엔씨. filed Critical 코크리스탈 파마, 아이엔씨.
Publication of KR20170137113A publication Critical patent/KR20170137113A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177030184A 2015-03-23 2016-03-23 C형 간염 바이러스 중합효소의 저해제 Abandoned KR20170137113A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136857P 2015-03-23 2015-03-23
US62/136,857 2015-03-23
PCT/US2016/023664 WO2016154241A1 (en) 2015-03-23 2016-03-23 Inhibitors of hepatitis c virus polymerase

Publications (1)

Publication Number Publication Date
KR20170137113A true KR20170137113A (ko) 2017-12-12

Family

ID=55759915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030184A Abandoned KR20170137113A (ko) 2015-03-23 2016-03-23 C형 간염 바이러스 중합효소의 저해제

Country Status (18)

Country Link
US (2) US10464914B2 (cg-RX-API-DMAC10.html)
EP (1) EP3274340B1 (cg-RX-API-DMAC10.html)
JP (1) JP6741747B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170137113A (cg-RX-API-DMAC10.html)
CN (1) CN107567442B (cg-RX-API-DMAC10.html)
AU (1) AU2016235246B2 (cg-RX-API-DMAC10.html)
CA (1) CA2979555C (cg-RX-API-DMAC10.html)
DK (1) DK3274340T3 (cg-RX-API-DMAC10.html)
EA (1) EA033622B1 (cg-RX-API-DMAC10.html)
ES (1) ES2748974T3 (cg-RX-API-DMAC10.html)
IL (1) IL254243B (cg-RX-API-DMAC10.html)
MX (1) MX379015B (cg-RX-API-DMAC10.html)
NZ (1) NZ735093A (cg-RX-API-DMAC10.html)
PH (1) PH12017501687A1 (cg-RX-API-DMAC10.html)
PL (1) PL3274340T3 (cg-RX-API-DMAC10.html)
SG (1) SG11201707527YA (cg-RX-API-DMAC10.html)
TW (1) TWI731854B (cg-RX-API-DMAC10.html)
WO (1) WO2016154241A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑
CN112203652A (zh) * 2018-05-09 2021-01-08 共晶制药公司 用于治疗hcv的组合疗法
CN112745216A (zh) * 2019-10-30 2021-05-04 常州锐博生物科技有限公司 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114181187A (zh) * 2021-11-24 2022-03-15 上海应用技术大学 一种4-甲磺酰胺基丁酰胺化合物的制备方法
CN116283512B (zh) * 2023-02-24 2025-04-25 博诺康源(北京)药业科技有限公司 一种合成维兰特罗及其盐的方法
IL328032A (en) * 2023-11-21 2026-06-01 Biohaven Therapeutics Ltd Trpm3-modulating benzofuran derivatives
CN119350612B (zh) * 2024-12-24 2025-10-24 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记聚乙二醇单甲醚的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980703048A (ko) 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1ｈ-인돌: 신규한 5-ｈｔ1ｆ 아고니스트
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
EP2363396A1 (en) 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US6936629B2 (en) 2001-12-21 2005-08-30 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US7265152B2 (en) * 2002-11-01 2007-09-04 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
ATE466856T1 (de) 2002-12-10 2010-05-15 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
AU2003291886A1 (en) 2002-12-10 2004-06-30 Virochem Pharma Inc. Thiophenederivatives for the treatment of flavivirus infections
DE60332482D1 (de) 2002-12-10 2010-06-17 Virochem Pharma Inc Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
WO2005113548A1 (en) 2004-05-20 2005-12-01 Sugen, Inc. Thiophene heteroaryl amines
DE102004061746A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Alkinyl-substituierte Thiophene
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
WO2007071434A1 (en) 2005-12-22 2007-06-28 Smithkline Beecham Corporation Antiviral 2-carboxy-thiophene compounds
WO2008017688A1 (en) 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
TW200815384A (en) 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
WO2008043791A2 (en) 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
SG176488A1 (en) 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
ATE524465T1 (de) 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
GB0707092D0 (en) 2007-04-12 2007-05-23 Smithkline Beecham Corp Compounds
GB0712393D0 (en) 2007-06-26 2007-08-01 Smithkline Beecham Corp Compounds
GB0718435D0 (en) * 2007-09-21 2007-10-31 Northern Health And Social Car Wpund care formulation
ATE539070T1 (de) 2008-02-14 2012-01-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
TW201136919A (en) * 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
AR082453A1 (es) * 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
US8771665B2 (en) 2010-12-17 2014-07-08 Cocrystal Discovery, Inc. Inhibitors of hepatitis C virus polymerase
WO2014055142A1 (en) 2012-06-20 2014-04-10 Cocrystal Discovery, Inc. Inhibitors of hepatitis c virus polymerase
TWI731854B (zh) * 2015-03-23 2021-07-01 美商共結晶製藥公司 Ｃ型肝炎病毒聚合酶之抑制劑

Also Published As

Publication number Publication date
CN107567442B (zh) 2021-05-25
IL254243A0 (en) 2017-10-31
US20200255393A1 (en) 2020-08-13
EP3274340A1 (en) 2018-01-31
TW201643147A (zh) 2016-12-16
WO2016154241A1 (en) 2016-09-29
PL3274340T3 (pl) 2020-01-31
JP2018512453A (ja) 2018-05-17
CA2979555A1 (en) 2016-09-29
HK1249514A1 (en) 2018-11-02
CA2979555C (en) 2023-12-19
SG11201707527YA (en) 2017-10-30
ES2748974T3 (es) 2020-03-18
TWI731854B (zh) 2021-07-01
IL254243B (en) 2020-10-29
HK1243703A1 (zh) 2018-07-20
AU2016235246B2 (en) 2020-12-10
MX379015B (es) 2025-03-10
CN107567442A (zh) 2018-01-09
EP3274340B1 (en) 2019-07-17
NZ735093A (en) 2022-09-30
US10464914B2 (en) 2019-11-05
AU2016235246A1 (en) 2017-09-21
US20180050998A1 (en) 2018-02-22
JP6741747B2 (ja) 2020-08-19
US10947210B2 (en) 2021-03-16
EA033622B1 (ru) 2019-11-11
BR112017020168A2 (pt) 2018-06-05
MX2017012238A (es) 2018-02-15
EA201792094A1 (ru) 2018-03-30
PH12017501687A1 (en) 2018-03-19
DK3274340T3 (da) 2019-10-07

Similar Documents

Publication Publication Date Title
US10947210B2 (en) Inhibitors of Hepatitis C virus polymerase
US11629125B2 (en) Elimination of hepatitis b virus with antiviral agents
TWI519515B (zh) Ｂ型肝炎抗病毒劑
US8771665B2 (en) Inhibitors of hepatitis C virus polymerase
US9321753B2 (en) Inhibitors of Flaviviridae viruses
TW201408687A (zh) 用於肝臟疾病之ｄ－胺基酸化合物
US20120202794A1 (en) Compounds
US10426762B2 (en) Inhibitors of hepatitis C virus polymerase
HK1249514B (en) Inhibitors of hepatitis c virus polymerase
WO2013139206A1 (zh) 3-氧代-3，4-二氢-2-吡嗪甲酰氨类衍生物、其药物组合物、其制备方法及用途
BR112017020168B1 (pt) Compostos inibidores de polimerase para o vírus da hepatite c, usos dos mesmos, bem como combinação
HK1243703B (en) Inhibitors of hepatitis c virus polymerase
EA041357B1 (ru) Противовирусные соединения для элиминации вируса гепатита b

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904